Anticholinergic Selection for Incontinence During Interstitial Cystitis Flares
All anticholinergic medications demonstrate equal efficacy for treating urgency urinary incontinence, including during interstitial cystitis flares, so selection should be based on tolerability rather than efficacy—specifically, choose tolterodine or darifenacin as they have discontinuation rates similar to placebo, or solifenacin which has the lowest overall discontinuation rate due to adverse effects. 1
The Evidence on Efficacy
The 2014 American College of Physicians guideline provides high-quality evidence that fundamentally answers this question: pharmacologic therapies were effective and equally efficacious at managing urgency UI 1. This is a critical finding—no single anticholinergic demonstrates superior efficacy over another for controlling incontinence symptoms 1, 2, 3.
The meta-analytic data shows:
- All anticholinergics reduce urge incontinence by approximately 1.73 episodes per day versus 1.06 with placebo 2
- All reduce voids by approximately 2.06 per day versus 1.2 with placebo 2
- The magnitude of benefit is moderate but consistent across agents 1
A 2000 study specifically examined intravesical oxybutynin in interstitial cystitis patients and found statistically significant improvement in all parameters including symptom problem index, voids per day, volume per void, and functional bladder capacity 4. However, this was intravesical administration, not oral.
Decision Algorithm Based on Tolerability
Since efficacy is equivalent, your choice should follow this hierarchy based on adverse effect profiles:
First Choice: Tolterodine or Darifenacin
- These are the only two anticholinergics with discontinuation rates due to adverse effects that are statistically similar to placebo 1
- This means patients are most likely to continue therapy long enough to see benefit
- Tolterodine: Start 2 mg twice daily (though 1 mg twice daily may be equally effective with less dry mouth) 1, 3
Second Choice: Solifenacin
- Solifenacin has the lowest risk for discontinuation due to adverse effects among all anticholinergics (NNTH 78) 1
- Start 5 mg once daily 1
- Superior to immediate-release tolterodine for efficacy and has less dry mouth 3
- Increasing to 10 mg does not improve efficacy but increases adverse effects 1
Avoid: Oxybutynin
- Oxybutynin has the highest risk for discontinuation due to adverse effects (NNTH 16) 1
- Highest rates of dry mouth and insomnia compared to other agents 1
- Despite being effective, poor tolerability undermines real-world outcomes
Formulation Considerations
If using oxybutynin or tolterodine, extended-release preparations have significantly less risk of dry mouth than immediate-release formulations 1, 3. Transdermal oxybutynin also reduces dry mouth but may cause skin reactions 3.
Critical Context for Interstitial Cystitis
The question specifically asks about IC flares. While the guideline evidence addresses urgency incontinence broadly, the ACP guideline recommends pharmacologic treatment for urgency UI only after bladder training has been unsuccessful 1. However, during an acute IC flare with severe urgency and incontinence, immediate pharmacologic intervention is reasonable.
Important caveat: The 2022 AUA guideline update for IC/BPS no longer uses hierarchical treatment tiers and emphasizes individualized, multimodal approaches 5, 6. Anticholinergics are just one component—consider concurrent behavioral modifications, dietary management, and pain control.
Common Pitfalls
Don't assume higher doses are better: With solifenacin, 10 mg doesn't improve efficacy over 5 mg but increases adverse effects 1
Don't ignore the placebo effect: Placebo reduces incontinence by 1.06 episodes/day, so modest improvements may not represent true drug effect 2
Don't expect complete resolution: Only 13-27% of patients achieve complete resolution of urgency incontinence with anticholinergics 7
Monitor for treatment failure: If no improvement after an adequate trial (typically 4-12 weeks), switch agents rather than continuing ineffective therapy 8